BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$145.13M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BridgeBio Oncology Therapeutics Inc.BridgeBio Oncology Therapeutics Inc.0--76%--
$19.00

Target Price by Analysts

949.7% upsideBridgeBio Oncology Therapeutics Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$145.13 Million
Enterprise Value$71.04 Million
Earnings per Share$-4.3
Beta0.39
Outstanding Shares80,184,540

Return

Return on Equity-75.82%ROE
Return on Assets-64.25%
Return on Invested Capital-63.44%

Valuation & Multiples

P/E Ratio0P/E Ratio
PEG0.01PEG
Price to Sales-Price to Sales
Price to Book Ratio0.6Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-0.38
Enterprise Value to Net Income-1
Total Debt to Enterprise0.03
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS Estimate
-$0.69
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 4, 2027
EPS Estimate
-$0.44
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %75117.81%▲ 898.70%
Total Invested$246.51M▼ 45.56%
Investors Holding85▲ 18.00%

About Helix Acquisition Corp. II

88 employees
CEO: Pedro J. Beltran

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the Unit...

Questions & Answers